Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-01-10 pm EST			5-day change	1st Jan Change
99.25 ^USD	-0.60%		+0.11%	-0.23%

Jan. 10	Atropos Health, Inc. Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments	CI
Jan. 09	IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma	MT

HSBC Upgrades Merck to Buy, Price Target at $130

December 04, 2024 at 05:17 am EST

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Merck & Co., Inc.

Atropos Health, Inc. Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments	Jan. 10	CI
IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma	Jan. 09	MT
Global markets live: Cintas, Amazon, Tesla, Shell, Lufthansa...	Jan. 08
Wall Street's rate cut dreams wane	Jan. 08
UBS Cuts Price Target on Merck to $120 From $125, Maintains Buy Rating	Jan. 08	MT
Merck: HPV vaccine for men approved in China	Jan. 08	CF
Merck Says Gardasil HPV Vaccine Approved for Males in China	Jan. 08	MT
Merck?s GARDASIL® Receives Expanded Approval for Males in China	Jan. 08	CI
Analyst recommendations: Adobe, Merck, Take-Two, Palantir, Experian...	Jan. 08
Truist Securities Downgrades Merck to Hold From Buy, Adjusts Price Target to $110 From $130	Jan. 08	MT
OPKO Health's ModeX Launches Phase 1 EBV Vaccine Candidate Trials With Merck	Jan. 07	MT
Merck Agrees to Acquire WuXi Biologics' Ireland Facility for $500 Million	Jan. 07	MT
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million	Jan. 07	DJ
Drug Companies to Raise Prices on 250 Branded Drugs in 2025	Jan. 03	MT
Drug Companies to Raise Prices on 250 Branded Drugs in 2025	Dec. 31	MT
Merck to Discontinue Zinplava for Clostridioides Difficile Infection	Dec. 24	MT
Merck: LM-299 antibody agreement finalized	Dec. 20	CF
Merck Closes Global License Deal for LM-299 with LaNova Medicines	Dec. 20	MT
Merck Closes Exclusive Global License Agreement for LM-299, an Investigational Anti-PD-1/VEGF Bispecific Antibody	Dec. 20	CI
BMO Capital Downgrades Merck & Co. to Market Perform From Outperform, Adjusts Price Target to $105 From $136	Dec. 20	MT
Analyst recommendations: Fedex, Merck, Nike, Coinbase, Tesla...	Dec. 20
Personalis Rallies Following $50 Million Investment from Merck, Extended Agreement With Moderna	Dec. 19	MT
Merck: encouraging phase III results in HIV	Dec. 19	CF
Merck Buys $50 Million of Personalis Stock	Dec. 19	DJ
Merck Says Investigational HIV Therapy Meets Primary Efficacy, Safety Goals in Phase 3 Trials	Dec. 19	MT

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (22.1%); - sale of animal health products (9.4%); - other (1.5%). Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).

Employees

71,000

Sector

Pharmaceuticals

Calendar

2025-01-13 - JP Morgan Healthcare Conference

More about the company